Skip to main content
. 2019 May 17;19:468. doi: 10.1186/s12885-019-5630-4

Table 2.

Treatment administered to patients with recurrent pancreatic ductal adenocarcinoma

Characteristics Number = 140 (%)
Chemotherapy for rPDAC
 Single Agent 19 (13)
 Non-Standard Combination 47 (34)
 Standard Combination 74 (53)
Lines of chemotherapy for rPDAC
 1 73 (52)
 2 47 (34)
 3 15 (11)
 4–6 5 (3)

rPDAC: recurrent pancreatic ductal adenocarcinoma